CFS Clinical (CFS), a provider focused on the business and financial management activities for clinical trials, announced the launch of its upgraded technology platform and new tax consulting services.
The InSite™ technology platform offers transparency for clinical trial operations, with reporting capabilities offering further visibility into investigator grant payments and study startup – including grant spend forecasting and modeling, Sunshine & global transparency compliance, enterprise site profiling, and more.
“CFS Clinical is the leader in our space and has always been a pioneer in clinical business operations. By adapting our solutions to the changing needs of sponsors, CROs, and sites, CFS continues to lead the way in transforming the business of clinical trials,” says Kevin Williams MBA/MS, Vice President of Corporate Development and Marketing for CFS Clinical.
In addition to the expanded business intelligence capabilities, CFS Clinical officially launched its Tax Consulting Service in January to help clients sort out the vast complexities of paying investigators globally.
“VAT rates range from 10-29%, and those rates are applied to millions of dollars of global grant payments.” states April Mulroney CPA, CA, Vice President of Global Tax, Treasury and Client Services based in CFS’s UK office. “CFS experts formalized this unique service to help our clients minimize financial risk and manage tax exposure on the largest line item in their clinical trial budget – the grant payments.”
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.